An Engineered Bivalent Neuregulin Protects Against Doxorubicin-Induced Cardiotoxicity With Reduced Proneoplastic Potential
Circulation - United States
doi 10.1161/circulationaha.113.002203
Full Text
Open PDFAbstract
Available in full text
Date
July 9, 2013
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)